血管紧张素Ⅱ2型受体基因多态性对钙拮抗剂降压疗效的影响
|
摘要
目的探讨血管紧张素Ⅱ2型受体基因多态性对钙拮抗剂降压疗效的影响,对钙拮抗剂与AT2受体基因多态性的关系做初步探索,为高血压的药物个体化治疗、疗效预测提供一定的理论依据。
对象和方法本研究的病例源于山东省济宁医学院附属医院心内科病房、门诊、健康查体中心,300例新发原发性轻、中度高血压患者,排除继发性高血压、急性心、脑血管病,以及心、肝、肾功能不全、未控制的糖尿病患者。实验前停用其他降压药物2周,测量基础血压后,第2天开始服用硝苯地平控释片(钙离子拮抗剂,商品名：拜新同)30mg／d,连续服用8周。测量患者诊室坐位右上臂血压,均采用水银袖带血压计,于开始服药后第2周、4周、6周、8周时上午测量,每次测量3次,取平均值。同时对患者进行体格检查及留取患者静脉血5mL,2%EDTA抗凝,测量生化指标和提取DNA。用聚合酶链反应(PCR)结合高分辨率熔解曲线(HRM)、基因测序方法检测患者的AT2受体基因多态性。观察AT2受体不同基因型与钙离子拮抗剂降压疗效的关系。
结果共300例患者入选了该实验,最终有229例患者完成了8周的实验,并成功的进行了全血基因组DNA的提取和多态性分析。女性患者116例,AA、AG及GG基因型分别为31例(26.7%)、62例(53.5%)和23例(19.8%),A和G等位基因频率分别为：53.4%和46.6%。治疗8周后基因型AA患者SBP及DBP降压幅度分别为：19.84±9.89和12.71±7.70,AG型患者降幅分别为：21.00±12.42和14.03±9.49,GG型患者降幅分别为：20.04±12.05mmHg和13.52±3.85mmHg；降压有效率分别为：71.0%、74.2%、76.0%；三组比较差异无统计学意义(p>0.05)。男性113例,AA型61例(54.0%),GG型52例(46.0%),AA型与GG型SBP、DBP降压幅度分别为：20.20±9.25mmHg和14.69±6.61mmHg,21.75±12.07mmHg和13.75±7.22mmHg；降压有效率分别为：73.8%和75.0%。在这两组患者中,降压幅度、治疗有效率的差异无统计学意义(P>0.05)。
结论1、AT2受体基因1675A／G多态性对钙拮抗剂(硝苯地平控释片)降压幅度及疗效无明显影响。
2、AT2受体基因1675A／G女性等位基因频率：A为53.4%、G为46.6%,男性等位基因频率：A为54.0%,G为46.0%,无论男、女等位基因频率与国内外同类研究结果基本一致。
3、长效钙拮抗剂(硝苯地平控释片)单药治疗轻、中度高血压效果确切,可作为其一线降压药物。
Objective To explore the effect of angiotensinⅡtype 2 receptor gene polymorphism on blood pressure response to CCB and to preliminarily discuss the relationship between CCB and AT2 receptor gene polymorphism so as to provide some scientific evidence for individual therapy and healing prediction.
Subjects and Methods In the research,300 new essential hypertension patients who were light and medium level were selected randomly from medicine-department clinic service,department of cordis and center of examination.Subjects with a history of cardiac or hepatic,diabetes mellitus were excluded,no symptoms of heart failure,stroke and lower-linber arterial disease. All patients have received Nifedipine Controlled Release Tablets (30mg/qd) for 8 weeks and no antihypertensive therapy for preceding two weeks,all patients'blood pressure were measured 3 times at 2,4,6,8week in the clinic service and mean value were registered as BP value. Took down their individual information (including name, sex, age, region, et al).Venous blood (5mL) were collected for measuring biochemical indicator and excluding DNA. The blood samples from the patients were collect to determine their AT2 receptor gene polymorphism by PCR combined with HRM,sequencing. The relationship among the genotypes of AT2 receptor to the therapeutic efficacy of Nifedipine was explored.
Results A total of 300 qualfied patients were enro11ed in the trial.229 patients completed the final 8-week trial. A whole blood genomic DNA extraction successfully conducted and and their data were used for the polymorphism analysis. Women with 116 cases,AA,AG and GG genotypes were 31 cases (26.7%),62 cases (53.5%) and 23 cases (19.8%), A and G allele frequencies were as follows:53.4% and 46.6%. After 8 weeks, in patients with AA genotype SBP and DBP, respectively decreasing amplitude:19.84±9.89 and 12.71±7.70, AG genotype patients, respectively drop amplitude:21.00±12.42 and 14.03±9.49, GG genotype patients, respectively drop amplitude:20.04±12.05mmHg and 13.52±3.85mmHg; Antihypertensive efficiency for three genotypes (AA、AG、GG) are as follows: 71.0%,74.2%,76.0%; three genotypes difference was not statistically significant (p> 0.05). Male 113 cases, AA genotype was 61 cases (54.0%), GG genotype was 52 cases (46.0%), AA genotype and GG genotype SBP, DBP drop range, respectively: 20.20±9.25mmHg and 14.69±6.61mmHg,21.75±12.07mmHg andl3.75±7.22mmHg;Antihypertensive efficiency for two genotypes(AA,GG)are as follows:73.8% and 75.0%. In both sets of patients, blood pressure reduction and the therapeutic efficacy of the difference were not statistically significant (P> 0.05).
Conclusion 1.The 1675A/G polymorphism of AT2 receptor gene was shown to no influence the response to CCB (Nifedipine Controlled Release Tablets).
2.AT2 receptor gene 1675A/G allele frequencies of women:A of 53.4%, G 46.6%, male allele frequencies:A of 54.0%, G 46.0%, both male and female allele frequencies at home and abroad Similar findings are basically consistent.
3. Confirmed that Nifedipine Controlled Release Tablets in patients with mild to moderate hypertension has antihypertensive effect of the exact.
对象和方法本研究的病例源于山东省济宁医学院附属医院心内科病房、门诊、健康查体中心,300例新发原发性轻、中度高血压患者,排除继发性高血压、急性心、脑血管病,以及心、肝、肾功能不全、未控制的糖尿病患者。实验前停用其他降压药物2周,测量基础血压后,第2天开始服用硝苯地平控释片(钙离子拮抗剂,商品名：拜新同)30mg／d,连续服用8周。测量患者诊室坐位右上臂血压,均采用水银袖带血压计,于开始服药后第2周、4周、6周、8周时上午测量,每次测量3次,取平均值。同时对患者进行体格检查及留取患者静脉血5mL,2%EDTA抗凝,测量生化指标和提取DNA。用聚合酶链反应(PCR)结合高分辨率熔解曲线(HRM)、基因测序方法检测患者的AT2受体基因多态性。观察AT2受体不同基因型与钙离子拮抗剂降压疗效的关系。
结果共300例患者入选了该实验,最终有229例患者完成了8周的实验,并成功的进行了全血基因组DNA的提取和多态性分析。女性患者116例,AA、AG及GG基因型分别为31例(26.7%)、62例(53.5%)和23例(19.8%),A和G等位基因频率分别为：53.4%和46.6%。治疗8周后基因型AA患者SBP及DBP降压幅度分别为：19.84±9.89和12.71±7.70,AG型患者降幅分别为：21.00±12.42和14.03±9.49,GG型患者降幅分别为：20.04±12.05mmHg和13.52±3.85mmHg；降压有效率分别为：71.0%、74.2%、76.0%；三组比较差异无统计学意义(p>0.05)。男性113例,AA型61例(54.0%),GG型52例(46.0%),AA型与GG型SBP、DBP降压幅度分别为：20.20±9.25mmHg和14.69±6.61mmHg,21.75±12.07mmHg和13.75±7.22mmHg；降压有效率分别为：73.8%和75.0%。在这两组患者中,降压幅度、治疗有效率的差异无统计学意义(P>0.05)。
结论1、AT2受体基因1675A／G多态性对钙拮抗剂(硝苯地平控释片)降压幅度及疗效无明显影响。
2、AT2受体基因1675A／G女性等位基因频率：A为53.4%、G为46.6%,男性等位基因频率：A为54.0%,G为46.0%,无论男、女等位基因频率与国内外同类研究结果基本一致。
3、长效钙拮抗剂(硝苯地平控释片)单药治疗轻、中度高血压效果确切,可作为其一线降压药物。
Objective To explore the effect of angiotensinⅡtype 2 receptor gene polymorphism on blood pressure response to CCB and to preliminarily discuss the relationship between CCB and AT2 receptor gene polymorphism so as to provide some scientific evidence for individual therapy and healing prediction.
Subjects and Methods In the research,300 new essential hypertension patients who were light and medium level were selected randomly from medicine-department clinic service,department of cordis and center of examination.Subjects with a history of cardiac or hepatic,diabetes mellitus were excluded,no symptoms of heart failure,stroke and lower-linber arterial disease. All patients have received Nifedipine Controlled Release Tablets (30mg/qd) for 8 weeks and no antihypertensive therapy for preceding two weeks,all patients'blood pressure were measured 3 times at 2,4,6,8week in the clinic service and mean value were registered as BP value. Took down their individual information (including name, sex, age, region, et al).Venous blood (5mL) were collected for measuring biochemical indicator and excluding DNA. The blood samples from the patients were collect to determine their AT2 receptor gene polymorphism by PCR combined with HRM,sequencing. The relationship among the genotypes of AT2 receptor to the therapeutic efficacy of Nifedipine was explored.
Results A total of 300 qualfied patients were enro11ed in the trial.229 patients completed the final 8-week trial. A whole blood genomic DNA extraction successfully conducted and and their data were used for the polymorphism analysis. Women with 116 cases,AA,AG and GG genotypes were 31 cases (26.7%),62 cases (53.5%) and 23 cases (19.8%), A and G allele frequencies were as follows:53.4% and 46.6%. After 8 weeks, in patients with AA genotype SBP and DBP, respectively decreasing amplitude:19.84±9.89 and 12.71±7.70, AG genotype patients, respectively drop amplitude:21.00±12.42 and 14.03±9.49, GG genotype patients, respectively drop amplitude:20.04±12.05mmHg and 13.52±3.85mmHg; Antihypertensive efficiency for three genotypes (AA、AG、GG) are as follows: 71.0%,74.2%,76.0%; three genotypes difference was not statistically significant (p> 0.05). Male 113 cases, AA genotype was 61 cases (54.0%), GG genotype was 52 cases (46.0%), AA genotype and GG genotype SBP, DBP drop range, respectively: 20.20±9.25mmHg and 14.69±6.61mmHg,21.75±12.07mmHg andl3.75±7.22mmHg;Antihypertensive efficiency for two genotypes(AA,GG)are as follows:73.8% and 75.0%. In both sets of patients, blood pressure reduction and the therapeutic efficacy of the difference were not statistically significant (P> 0.05).
Conclusion 1.The 1675A/G polymorphism of AT2 receptor gene was shown to no influence the response to CCB (Nifedipine Controlled Release Tablets).
2.AT2 receptor gene 1675A/G allele frequencies of women:A of 53.4%, G 46.6%, male allele frequencies:A of 54.0%, G 46.0%, both male and female allele frequencies at home and abroad Similar findings are basically consistent.
3. Confirmed that Nifedipine Controlled Release Tablets in patients with mild to moderate hypertension has antihypertensive effect of the exact.
引文
[1]李立明,饶克勤,孔灵芝,等.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7)：478-484.
[2]全国高血压抽样调查协作组.中国高血压的患病率及其变化趋势[J].中国高血压杂志,1995,3(S1)：7-18.
[3]洪静,聂敏,孙梅励,等.血管紧张素转化酶2的病理生理作用[J].基础医学与临床,2008,28(9)：994-997.
[4]Patrick M. Sonnerl, Jessica A. Filosal, Javier E. Sternl. J. Physiol., Mar 2008,586 (6):1605-1622.
[5]刘国仗,胡大一,陶萍,等.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,2005,26(1)：5-11.
[6]Mark G, Herrmann, Jacob D, Durtschi, et al. Amplicon DNA Melting Analysis for Mutation Scanning and Genotyping:Cross-Platform Comparison of Instruments and Dyes[J].Clin Chem,2006,52 (3):494-503.
[7]Michael Liew, Michael Seipp, Jacob Durtschi, et al. Closed-Tube SNP Genotyping Without Labeled Probes A Comparison Between Unlabeled Probe and Amplicon Melting[J]. Am J Clin Pathol,2007,127 (3):341-348.
[8]Schelleman H, Klungel OH, van Dui jn CM, et al. Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy[J]. The Annals of Pharmacotherapy,2006,40(2):212-218.
[9]Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hypertension[J]. Pharmacological Research,2004,49(4): 351-356.
[10]Turner ST, Schwartz GL. Gene markers and antihypertensive therapy [J]. Current Hypertension reports,2005,7(1):21-30.
[11]ArnettDK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment[J]. Vascular Pharmacology,2006,44(2): 107-118.
[12]陶霞,刘皋林.药物基因组学与高血压病的药物选择[J].中国临床药理学与治疗学,2002,7(3)：263-268.
[13]Linda J, Mullins, Matthew A, et al. Hypertension, kidney, and transgenics:A fresh perspective [J].Physiol Rev,2006,86 (2):709-746.
[14]Cusi D, Bianchi G. A primer on the genetics of hypertension. Kidney Int,1998,54 (2):328-342.
[15]Li Z, Iwai M, Wu L, etal. Role of AT2receptor in the brain in regulation of blood pressure and water intake [J]. Am J Physiol Heart Circ Physiol,2003,284:H116-121.
[16]Utsunomiya H, Nakamura M, Kakudo K, et al. AngiotensinⅡ AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice [J]. Regul Pept,2005,126:155-161.
[17]Katada J, Majima M. AT2 receptor-dependent vasodilation is me-diated by activation of vascular kinin generation under flow condi-tions[J].Br J Pharmacol,2002,136:484-491.
[18]Yayama K, Horii M, Hiyoshi H, et al. Up-Regulation of AngioensinⅡType 2 Receptor in Rat Thoracic Aorta by Pressure overload[J]. Pharmacol Exp Ther,2004,308(2):736-743.
[19]Cresci B, Giannini S, Pala L, et al. ATland AT2receptors in human glomerular endothelial cells at different passages[J]. Microvasc Res,2003,66:22-29.
[20]Tsuzuki S, Iehiki T,Nakakubo H, et al. Molecular cloning and expression of the gene enconing human angiotensin Ⅱ type2 receptor[J]. Bioehem Biophys Res Commun,1994,200:1449-1454.
[21]Martin MM, Elton TS.The sequence and genetic organization of the human type 2 angiotensin Ⅱ receptor[J]. Biochem Biophys Res Commun,1995,209:554-562.
[22]Ichiki T,Inagami T.Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene[J].Circ Res,1995,76(5):693-700.
[23]Warnecke C, Willich T, Holzmeister J, et al. Efficient transcription of the huma angiotensin Ⅱ type 2 receptor gene requires intronic sequence elements[J]. Biochem J,1999,340:17-24.
[24]周平,李法琦,马厚助,血管紧张素Ⅱ-2型受体基因A1675G多态性与原发性高血压的相关性研究[J].重庆医科大学学报,2005,30(6)：836-839.
[25]Sehmieder RE, Erdmann J, Delles C, e tal. Effect of the angiotensin II type2 receptor gene (+1675G/A) on left ventricular structure in humans[J]. Jam Coll Cardiol,2001,37(1):175-182.
[26]Alfakih K, Maqbool A, Sivannthan M, et al. Left Ventricule Mass Index and the Common, Functional, X-Linked Angiotensin II type2 Receptor Gene ploymorphism(-1332G/A) in patients with System Hypertension[J]. Hypertension,2004,43:1189-1194.
[27]Jaehylllova M, Hokry K, Bultas J, et al. Association of the Glu 298 Aps Polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun,2001,284 (2):426-430.
[28]Szombathy, TSzalaiC, KatalinB, etal. Association of angiotensin Ⅱ typel recptor Polymorphims with resistant essential hypertension. Clin Chim Acta,1998,269(1):91-100.
[29]Leeson CP Hingorani AD, Mullen MJ, etal. Glu298AsP endothelial nitric Oxide synthase gene Polylimorphism interacts with enviornmental and dietary factors to influence endothelial function. Cicr Res,2002,90(11):1153-1158.
[30]ohmichiN, IwaiN, UchidaY, etal. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotye. AmJ Hypensrtens 1997, Aug:10 (8):951-955.
[31]Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan [J]. Pharmacol,2002,445:151-152.
[32]Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme. gene polymorphism predicts blood pressure response to an2giotensin II receptor type 1 antagonist treatment in hypertensive patients [J]. Hypertension,2001,19:1783-1787.
[33]吴寿岭,李云,刘克俭,等.血管紧张素转换酶和醛固酮合成酶基因多态性与氢氯噻嗪降压疗效的关系[J].中华心血管病杂志,2005,33(7)：595-598.
[34]Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/Tpolymorphism is related to antihypertensive response [J]. Hypertension,2002,15:389-393.
[35]Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol[J]. Clin Pharmacol Ther,2003,74:44-52.
[36]Karlsson J, LindL, Hallberg P, et al. Betal-adrenergic receptor gene polymorphisms and response to beta 1-adrenergic receptor blockade in patients with essential hypertension [J]. Clin Cardiol,2004,27:347-350.
[37]0'Shaughnessy KM, FuB, Dickerson C, et al. The gainof-function G389R variant of the betal-adrenoceptor does not influence blood pressure orheart rate response to beta-blocker in hypertensive subjects [J]. Clinici (Lond),2000,99:233-238.
[38]Brown MJ, Palmer CR, Castaigne A. et al. Mor-bidity and mortality in patients, randomized to double-blind treatment with a long-acting ca lcium-channel blocker or diuretic in the International Nifedipine GITS study:Intervention as a Goal in Hypertension Treatment(INSIGHT). Lancet.2000,356(9227):366-372.
[39]马艳红.药物、指南多治疗、控制率低—我国降压治疗现状不容乐观[N].中国医药报,2007-10-16(B6).
[40]张佳,廖端芳,张旭,等.高保真DNA聚合酶在SNP检测中的应用[J].南华大学学报医学版,2003,31(2)：128-131.
[41]Zhang J, Li K, Liao D, et al. Different application of polymerase with and without proofreading activity in single-nucleotide polymorphism analysis. Lab Invest,2003,83(8):1147-1154.
[42]彭翠英,廖端芳,张佳,等.单核苷酸多态性及其检测方法[J].中华检验医学杂志.2004,27(10)：703-705.
[43]黄妤,黄国庆,高分辨率熔解-SNP及突变研究的最新工具[J].生命的化学.2007,27(6)：573-576.
[1]Csikos T, Chung 0, Unger T, et al. Receptors and their classification: focus on angiotensin Hand the AT2 receptor[J]. J Hum Hypertens, 1998,12 (5):311-318.
[2]孟永,李芳,张敏,等.血管紧张素Ⅱ-2型受体在心脏保护方面的研究进展[J].心血管病学进展,2007,28(6)：921-923.
[3]Kawano H,Do YS,Kawano Y, et al. Angiotensin Ⅱ has multiple profibrotic effects in Human cardiac fibroblasts[J]. Circulation,2000,101 (10): 1130-1137.
[4]杨丽霞,祝善俊.心脏血管紧张素Ⅱ受体研究进展[J].心血管病学进展,2003,24(2)：81-84.
[5]刘永胜,王晋明,张庆华.AT1受体的研究进展[J].心血管病学进展,2003,24(2) ：84-86.
[6]罗能钦,金杰.良性前列腺增生合并高血压患者前列腺中血管紧张素Ⅱ及其受体ATl分布及表达的研究[J].中国男科学杂志,,2008,22(4)：40-42.
[7]Li Z, Iwai M, Wu L, et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake[J]. Am J Physiol Heart Circ Physiol,2003,284(1):H116-H121.
[8]Wang YB, Chen M. Advance in research of Angiotensin Ⅱ type 2 receptor in cardiovascular system[J]. Adv CardiovascDis,2005, 26(4):428-431.
[9]Meng Y, LI F, Zhang M, et al. Advances in research of Angiotensin II receptor[J]. Adv Cardiovasc Dis,2007,28(6):921-924.
[10]Bienvenu T, Poirier K, Van Eseh H, et al. Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation [J]. J Med Genet,2003,40 (11):357-359.
[11]Warnecke C, Mugrauer P, Surder D, et al. Intronic ANGII type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing[J]. Am J Physiol Regul Integr Comp Physiol, 2005,289 (6):1729-1735.
[12]乔卫卫,张奎星,刘同宝,等.血管紧张素Ⅱ2型受体基因多态性与男性高血压病的相关研究[J].中华心血管病杂志,2005,33(7)：592-594.
[13]Lajemi M, Labat C, Gautier S, et al. Angiotensin Ⅱ type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects [J]. J Hypertens, 2001,199 (3):407-413.
[14]Zhu S, Meng QH. Association of angiotensin II type 1 receptor gene polymorphism with carotid atherosclerosis[J].Clin Chem Lab Med, 2006,44 (3):282-284.
[15]Fabris B, Bortoletto M, Candido R, et al. Genetic polymorphisms of the renin-angiotensin-aldosteronesystem and renal insufficiency in essential hypertension[J]. J Hypertens,2005,23(2):309-316.
[16]Osawa N, Koya D, Araki S, et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy[J].J Hum Genet,2007,52(2):143-151.
[17]Alfakih K, Maqbool A, Sivananthan M, et al. Left ventricle mass index and the common, functional, X-linked angiotensin Ⅱ type-2 receptor gene polymorphism (-1332G/A) in patients with systemic hypertension [J]. Hypertension,2004,43(6):1189-1194.
[18]王曦云,崔俊彪,盛莉,等.血管紧张素Ⅱ2型受体基因及醛固酮合成酶基因多态性与高血压左室肥厚相关性研究[J].中华心血管病杂志,2005,33(7)：621-625.
[19]Alfakih K, Lawrance RA, Maqbool A, et al. The clinical significance of a common, functional, X-linked angiotensin II type 2-recepto gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease[J]. Eur Heart J,2005,26(6):584-589.
[20]Herrmann SM, Nicaud V, Schmidt-Petersen K, et al. Angiotensin I type 2 receptor gene polymorphism and cardiovascular phenotypes:the GLAECO and GLAOLD studies[J].Eur J Heart Fail,2002,4(6):707-712.
[21]Rigoli L, Chimenz R, diBella C, et al. Angiotensin-converting enzyme and angiotensin type 2 receptor gene genotype distributions In Italian angiotensin type 2 receptor gene genotype distributions In Italian children with congenital uropathies[J]. Pediatr Res,2004, 56(6):988-993.
[22]Pettersson-Fernholm K, Frojdo S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients [J]. Kidney Int,2006,69(10):1880-1884.
[23]Nickenig G. Should angiotension 2 receptor blockers and statins be combined?[J]. Circulation,2004,110(8):1013-1014.
[24]余静,刘先哲.动脉粥样硬化中血管紧张素Ⅱ对血管平滑肌细胞的作用[J].中华医学研究杂志,2008,8(2)：128-131.
[25]Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype?[J].Br J Pharmacol,2003, 140(5):809-824.
[26]Carey RM. Update on the role of the AT2 receptor[J]. Circ Hemody namics,2005,14(1):67-71.
[27]Sales VL, Sukhova GK, Lopez-Ilasaca MA, et al. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution[J]. Circulation,2005,112(21): 3328-3336.
[28]Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensinⅡtype-2 receptors[J]. Cardiovasc Res,2004, 62(3):460-467.
[29]Kuznetsova T, Staessen JA, Thi js L, et al. Left ventricular mass in relation to genetic variation in angiotensinII receptors, renin system genes, and sodium excretion[J]. Circulation,2004, 110(17):2644-2650.
[30]Liu YH, Yang XP, Shesely EG, et al. Role of angiotensinⅡ type 2 receptors and kinins in the cardioprotective effect of angiotensinⅡ type 1 receptor antagonists in rats with heart failure[J]. J Am Coll Cardiol,2004,43(8):1473-1480.
[31]Busche S, GallinatS, Bohle RM, et al. Expression of angiotensin AT1 and AT2 receptors in adult rat cardiomyocytes after myocardial infarction. A single cell reverse transcriptase polymerase chain reaction study[J]. Am J Pathol,2000,157(2):605-611.
[32]Tsutsumi Y, Matsubara H, Ohkubo N, etal. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression[J]. Circulation Research,1998,83(10):1035-1046.
[33]D'Amore A, Black J, Thomas W. The angiotensin Ⅱ type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin Ⅱ type 1 receptor-mediated hypertrOphy[J]. Hypertension,2005,46(6):1347-1354
[2]全国高血压抽样调查协作组.中国高血压的患病率及其变化趋势[J].中国高血压杂志,1995,3(S1)：7-18.
[3]洪静,聂敏,孙梅励,等.血管紧张素转化酶2的病理生理作用[J].基础医学与临床,2008,28(9)：994-997.
[4]Patrick M. Sonnerl, Jessica A. Filosal, Javier E. Sternl. J. Physiol., Mar 2008,586 (6):1605-1622.
[5]刘国仗,胡大一,陶萍,等.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,2005,26(1)：5-11.
[6]Mark G, Herrmann, Jacob D, Durtschi, et al. Amplicon DNA Melting Analysis for Mutation Scanning and Genotyping:Cross-Platform Comparison of Instruments and Dyes[J].Clin Chem,2006,52 (3):494-503.
[7]Michael Liew, Michael Seipp, Jacob Durtschi, et al. Closed-Tube SNP Genotyping Without Labeled Probes A Comparison Between Unlabeled Probe and Amplicon Melting[J]. Am J Clin Pathol,2007,127 (3):341-348.
[8]Schelleman H, Klungel OH, van Dui jn CM, et al. Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy[J]. The Annals of Pharmacotherapy,2006,40(2):212-218.
[9]Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hypertension[J]. Pharmacological Research,2004,49(4): 351-356.
[10]Turner ST, Schwartz GL. Gene markers and antihypertensive therapy [J]. Current Hypertension reports,2005,7(1):21-30.
[11]ArnettDK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment[J]. Vascular Pharmacology,2006,44(2): 107-118.
[12]陶霞,刘皋林.药物基因组学与高血压病的药物选择[J].中国临床药理学与治疗学,2002,7(3)：263-268.
[13]Linda J, Mullins, Matthew A, et al. Hypertension, kidney, and transgenics:A fresh perspective [J].Physiol Rev,2006,86 (2):709-746.
[14]Cusi D, Bianchi G. A primer on the genetics of hypertension. Kidney Int,1998,54 (2):328-342.
[15]Li Z, Iwai M, Wu L, etal. Role of AT2receptor in the brain in regulation of blood pressure and water intake [J]. Am J Physiol Heart Circ Physiol,2003,284:H116-121.
[16]Utsunomiya H, Nakamura M, Kakudo K, et al. AngiotensinⅡ AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice [J]. Regul Pept,2005,126:155-161.
[17]Katada J, Majima M. AT2 receptor-dependent vasodilation is me-diated by activation of vascular kinin generation under flow condi-tions[J].Br J Pharmacol,2002,136:484-491.
[18]Yayama K, Horii M, Hiyoshi H, et al. Up-Regulation of AngioensinⅡType 2 Receptor in Rat Thoracic Aorta by Pressure overload[J]. Pharmacol Exp Ther,2004,308(2):736-743.
[19]Cresci B, Giannini S, Pala L, et al. ATland AT2receptors in human glomerular endothelial cells at different passages[J]. Microvasc Res,2003,66:22-29.
[20]Tsuzuki S, Iehiki T,Nakakubo H, et al. Molecular cloning and expression of the gene enconing human angiotensin Ⅱ type2 receptor[J]. Bioehem Biophys Res Commun,1994,200:1449-1454.
[21]Martin MM, Elton TS.The sequence and genetic organization of the human type 2 angiotensin Ⅱ receptor[J]. Biochem Biophys Res Commun,1995,209:554-562.
[22]Ichiki T,Inagami T.Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene[J].Circ Res,1995,76(5):693-700.
[23]Warnecke C, Willich T, Holzmeister J, et al. Efficient transcription of the huma angiotensin Ⅱ type 2 receptor gene requires intronic sequence elements[J]. Biochem J,1999,340:17-24.
[24]周平,李法琦,马厚助,血管紧张素Ⅱ-2型受体基因A1675G多态性与原发性高血压的相关性研究[J].重庆医科大学学报,2005,30(6)：836-839.
[25]Sehmieder RE, Erdmann J, Delles C, e tal. Effect of the angiotensin II type2 receptor gene (+1675G/A) on left ventricular structure in humans[J]. Jam Coll Cardiol,2001,37(1):175-182.
[26]Alfakih K, Maqbool A, Sivannthan M, et al. Left Ventricule Mass Index and the Common, Functional, X-Linked Angiotensin II type2 Receptor Gene ploymorphism(-1332G/A) in patients with System Hypertension[J]. Hypertension,2004,43:1189-1194.
[27]Jaehylllova M, Hokry K, Bultas J, et al. Association of the Glu 298 Aps Polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun,2001,284 (2):426-430.
[28]Szombathy, TSzalaiC, KatalinB, etal. Association of angiotensin Ⅱ typel recptor Polymorphims with resistant essential hypertension. Clin Chim Acta,1998,269(1):91-100.
[29]Leeson CP Hingorani AD, Mullen MJ, etal. Glu298AsP endothelial nitric Oxide synthase gene Polylimorphism interacts with enviornmental and dietary factors to influence endothelial function. Cicr Res,2002,90(11):1153-1158.
[30]ohmichiN, IwaiN, UchidaY, etal. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotye. AmJ Hypensrtens 1997, Aug:10 (8):951-955.
[31]Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan [J]. Pharmacol,2002,445:151-152.
[32]Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme. gene polymorphism predicts blood pressure response to an2giotensin II receptor type 1 antagonist treatment in hypertensive patients [J]. Hypertension,2001,19:1783-1787.
[33]吴寿岭,李云,刘克俭,等.血管紧张素转换酶和醛固酮合成酶基因多态性与氢氯噻嗪降压疗效的关系[J].中华心血管病杂志,2005,33(7)：595-598.
[34]Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/Tpolymorphism is related to antihypertensive response [J]. Hypertension,2002,15:389-393.
[35]Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol[J]. Clin Pharmacol Ther,2003,74:44-52.
[36]Karlsson J, LindL, Hallberg P, et al. Betal-adrenergic receptor gene polymorphisms and response to beta 1-adrenergic receptor blockade in patients with essential hypertension [J]. Clin Cardiol,2004,27:347-350.
[37]0'Shaughnessy KM, FuB, Dickerson C, et al. The gainof-function G389R variant of the betal-adrenoceptor does not influence blood pressure orheart rate response to beta-blocker in hypertensive subjects [J]. Clinici (Lond),2000,99:233-238.
[38]Brown MJ, Palmer CR, Castaigne A. et al. Mor-bidity and mortality in patients, randomized to double-blind treatment with a long-acting ca lcium-channel blocker or diuretic in the International Nifedipine GITS study:Intervention as a Goal in Hypertension Treatment(INSIGHT). Lancet.2000,356(9227):366-372.
[39]马艳红.药物、指南多治疗、控制率低—我国降压治疗现状不容乐观[N].中国医药报,2007-10-16(B6).
[40]张佳,廖端芳,张旭,等.高保真DNA聚合酶在SNP检测中的应用[J].南华大学学报医学版,2003,31(2)：128-131.
[41]Zhang J, Li K, Liao D, et al. Different application of polymerase with and without proofreading activity in single-nucleotide polymorphism analysis. Lab Invest,2003,83(8):1147-1154.
[42]彭翠英,廖端芳,张佳,等.单核苷酸多态性及其检测方法[J].中华检验医学杂志.2004,27(10)：703-705.
[43]黄妤,黄国庆,高分辨率熔解-SNP及突变研究的最新工具[J].生命的化学.2007,27(6)：573-576.
[1]Csikos T, Chung 0, Unger T, et al. Receptors and their classification: focus on angiotensin Hand the AT2 receptor[J]. J Hum Hypertens, 1998,12 (5):311-318.
[2]孟永,李芳,张敏,等.血管紧张素Ⅱ-2型受体在心脏保护方面的研究进展[J].心血管病学进展,2007,28(6)：921-923.
[3]Kawano H,Do YS,Kawano Y, et al. Angiotensin Ⅱ has multiple profibrotic effects in Human cardiac fibroblasts[J]. Circulation,2000,101 (10): 1130-1137.
[4]杨丽霞,祝善俊.心脏血管紧张素Ⅱ受体研究进展[J].心血管病学进展,2003,24(2)：81-84.
[5]刘永胜,王晋明,张庆华.AT1受体的研究进展[J].心血管病学进展,2003,24(2) ：84-86.
[6]罗能钦,金杰.良性前列腺增生合并高血压患者前列腺中血管紧张素Ⅱ及其受体ATl分布及表达的研究[J].中国男科学杂志,,2008,22(4)：40-42.
[7]Li Z, Iwai M, Wu L, et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake[J]. Am J Physiol Heart Circ Physiol,2003,284(1):H116-H121.
[8]Wang YB, Chen M. Advance in research of Angiotensin Ⅱ type 2 receptor in cardiovascular system[J]. Adv CardiovascDis,2005, 26(4):428-431.
[9]Meng Y, LI F, Zhang M, et al. Advances in research of Angiotensin II receptor[J]. Adv Cardiovasc Dis,2007,28(6):921-924.
[10]Bienvenu T, Poirier K, Van Eseh H, et al. Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation [J]. J Med Genet,2003,40 (11):357-359.
[11]Warnecke C, Mugrauer P, Surder D, et al. Intronic ANGII type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing[J]. Am J Physiol Regul Integr Comp Physiol, 2005,289 (6):1729-1735.
[12]乔卫卫,张奎星,刘同宝,等.血管紧张素Ⅱ2型受体基因多态性与男性高血压病的相关研究[J].中华心血管病杂志,2005,33(7)：592-594.
[13]Lajemi M, Labat C, Gautier S, et al. Angiotensin Ⅱ type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects [J]. J Hypertens, 2001,199 (3):407-413.
[14]Zhu S, Meng QH. Association of angiotensin II type 1 receptor gene polymorphism with carotid atherosclerosis[J].Clin Chem Lab Med, 2006,44 (3):282-284.
[15]Fabris B, Bortoletto M, Candido R, et al. Genetic polymorphisms of the renin-angiotensin-aldosteronesystem and renal insufficiency in essential hypertension[J]. J Hypertens,2005,23(2):309-316.
[16]Osawa N, Koya D, Araki S, et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy[J].J Hum Genet,2007,52(2):143-151.
[17]Alfakih K, Maqbool A, Sivananthan M, et al. Left ventricle mass index and the common, functional, X-linked angiotensin Ⅱ type-2 receptor gene polymorphism (-1332G/A) in patients with systemic hypertension [J]. Hypertension,2004,43(6):1189-1194.
[18]王曦云,崔俊彪,盛莉,等.血管紧张素Ⅱ2型受体基因及醛固酮合成酶基因多态性与高血压左室肥厚相关性研究[J].中华心血管病杂志,2005,33(7)：621-625.
[19]Alfakih K, Lawrance RA, Maqbool A, et al. The clinical significance of a common, functional, X-linked angiotensin II type 2-recepto gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease[J]. Eur Heart J,2005,26(6):584-589.
[20]Herrmann SM, Nicaud V, Schmidt-Petersen K, et al. Angiotensin I type 2 receptor gene polymorphism and cardiovascular phenotypes:the GLAECO and GLAOLD studies[J].Eur J Heart Fail,2002,4(6):707-712.
[21]Rigoli L, Chimenz R, diBella C, et al. Angiotensin-converting enzyme and angiotensin type 2 receptor gene genotype distributions In Italian angiotensin type 2 receptor gene genotype distributions In Italian children with congenital uropathies[J]. Pediatr Res,2004, 56(6):988-993.
[22]Pettersson-Fernholm K, Frojdo S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients [J]. Kidney Int,2006,69(10):1880-1884.
[23]Nickenig G. Should angiotension 2 receptor blockers and statins be combined?[J]. Circulation,2004,110(8):1013-1014.
[24]余静,刘先哲.动脉粥样硬化中血管紧张素Ⅱ对血管平滑肌细胞的作用[J].中华医学研究杂志,2008,8(2)：128-131.
[25]Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype?[J].Br J Pharmacol,2003, 140(5):809-824.
[26]Carey RM. Update on the role of the AT2 receptor[J]. Circ Hemody namics,2005,14(1):67-71.
[27]Sales VL, Sukhova GK, Lopez-Ilasaca MA, et al. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution[J]. Circulation,2005,112(21): 3328-3336.
[28]Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensinⅡtype-2 receptors[J]. Cardiovasc Res,2004, 62(3):460-467.
[29]Kuznetsova T, Staessen JA, Thi js L, et al. Left ventricular mass in relation to genetic variation in angiotensinII receptors, renin system genes, and sodium excretion[J]. Circulation,2004, 110(17):2644-2650.
[30]Liu YH, Yang XP, Shesely EG, et al. Role of angiotensinⅡ type 2 receptors and kinins in the cardioprotective effect of angiotensinⅡ type 1 receptor antagonists in rats with heart failure[J]. J Am Coll Cardiol,2004,43(8):1473-1480.
[31]Busche S, GallinatS, Bohle RM, et al. Expression of angiotensin AT1 and AT2 receptors in adult rat cardiomyocytes after myocardial infarction. A single cell reverse transcriptase polymerase chain reaction study[J]. Am J Pathol,2000,157(2):605-611.
[32]Tsutsumi Y, Matsubara H, Ohkubo N, etal. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression[J]. Circulation Research,1998,83(10):1035-1046.
[33]D'Amore A, Black J, Thomas W. The angiotensin Ⅱ type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin Ⅱ type 1 receptor-mediated hypertrOphy[J]. Hypertension,2005,46(6):1347-1354